ReviewFrontiers in oncology2013
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors.
Review in Frontiers in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Eliciting antitumor immunity via therapeutic cancer vaccines.Cellular & molecular immunology · 2025Review
- Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.Journal for immunotherapy of cancer · 2024Article
- Genome-wide identification of endogenous retrovirus elements and their active transcription in mink genome.mLife · 2023Article
- The Immunological Conundrum of Endogenous Retroelements.Annual review of immunology · 2023Review
- Endogenous retrovirus group FRD member 1 is a potential biomarker for prognosis and immunotherapy for kidney renal clear cell carcinoma.Frontiers in cellular and infection microbiology · 2023Article
- The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications.American journal of physiology. Cell physiology · 2022Review
- PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner.Cancer immunology research · 2022Article
- HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome.NPJ genomic medicine · 2021Article
- Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma.Frontiers in oncology · 2021Article
- Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.Cancers · 2020Review
- At the end of the beginning: immunotherapies as living drugs.Nature immunology · 2019Article
- Retrovirus insertion site analysis of LGL leukemia patient genomes.BMC medical genomics · 2019Article
- Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models.Cancer immunology research · 2018Article
- Making a virtue of necessity: the pleiotropic role of human endogenous retroviruses in cancer.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Review
- Downregulation of Human Endogenous Retrovirus Type K (HERV-K) ViralClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Interplay between viruses and bacterial microbiota in cancer development.Seminars in immunology · 2017Review
- Immune responses to endogenous retroelements: taking the bad with the good.Nature reviews. Immunology · 2016Review
- Expression of evolutionarily novel genes in tumors.Infectious agents and cancer · 2016Review
- The decline of human endogenous retroviruses: extinction and survival.Retrovirology · 2015Article
- Unfixed endogenous retroviral insertions in the human population.Journal of virology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of human genome. Most HERVs have accumulated mutations and deletions that prevent their expression as an infectious virus. Nevertheless, a growing number of HERV genes and proteins have been found to be expressed in different cancers, raising the possibility that HERV-derived antigens might represent excellent targets for tumor immunotherapy. Here, we review data showing HERV-encoded antigens are capable of eliciting humoral and T-cells specific antitumor immunity. We also describe a novel HERV-E that was recently found to be selectively expressed in over 80% of clear cell kidney cancer but not in normal tissues. Remarkably, the restricted expression of HERV-E in kidney tumors was found to occur as a consequence of inactivation of the von Hippel-Lindau tumor suppressor. Importantly, antigens derived from this provirus are immunogenic, stimulating cytotoxic T-cells that kill kidney cancer cells in vitro and in vivo. Taken altogether, these data suggest efforts aimed at boosting human immunity against HERV-derived antigens could be used as a strategy to treat advanced tumors including kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.